Evidence map›Paper›PMID 25210168›Full record

ArticleJournal of virology2014

Early preservation of CXCR5+ PD-1+ helper T cells and B cell activation predict the breadth of neutralizing antibody responses in chronic HIV-1 infection.

Kristen Cohen, Marcus Altfeld, Galit Alter, Leonidas Stamatatos

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 74 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. HIV-1-Infected CD4Journal of immunology (Baltimore, Md. : 1950) · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. TFrontiers in immunology · 2020
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Kristen CohenSeattle Biomedical Research Institute, Seattle, Washington, USA University of Washington, Department of Global Health, Seattle, Washington, USA.
Marcus AltfeldRagon Institute of MGH, MIT, and Harvard, Massachusetts General Hospital, Boston, Massachusetts, USA Heinrich-Pette-Institut, Hamburg, Germany.
Galit AlterRagon Institute of MGH, MIT, and Harvard, Massachusetts General Hospital, Boston, Massachusetts, USA.
Leonidas StamatatosSeattle Biomedical Research Institute, Seattle, Washington, USA University of Washington, Department of Global Health, Seattle, Washington, USA leo.stamatatos@seattlebiomed.org.
Ragon Institute of MGH, MIT and Harvard · USCenter for Infectious Disease Research · USUniversity of Washington · US

Funding

Washington National Primate Research CenterP51OD010425 · OD · UNIVERSITY OF WASHINGTON · PI Mari Ostendorf · 2012 to 2026
$201.8M
Vaccination design based on natural env genes to elicit broad neutralizing AbsP01AI078064 · NIAID · OREGON HEALTH & SCIENCE UNIVERSITY · PI HAIGWOOD, NANCY L · 2009 to 2014
$12.1M
Monitoring the development of anti-Env Abs during HIV infectionR01AI081625 · NIAID · SEATTLE BIOMEDICAL RESEARCH INSTITUTE · PI STAMATATOS, LEONIDAS · 2010 to 2020
$5.8M
NIAID NIH HHS P01 AI078064NIAID NIH HHS R01 AI081625NIH HHS P51 OD010425PHS HHS NIAID R01AI081625
6 · The paper itself

Abstract

unlabelledMuch is known about the characteristics of broadly neutralizing antibodies (bNAbs) generated during HIV-1 infection, but little is known about immunological mechanisms responsible for their development in only a minority of those infected by HIV-1. By monitoring longitudinally a cohort of HIV-1-infected subjects, we observed that the preservation of CXCR5(+) CD4(+) T helper cell frequencies and activation status of B cells during the first year of infection correlates with the maximum breadth of plasma neutralizing antibody responses during chronic infection independently of viral load. Although, during the first year of infection, no differences were observed in the abilities of peripheral CXCR5(+) CD4(+) T helper cells to induce antibody secretion by autologous naive B cells, higher frequencies of class-switched antibodies were detected in cocultures of CXCR5(+) CD4(+) T and B cells from the subjects who later developed broadly neutralizing antibody responses than those who did not. Furthermore, B cells from the former subjects had higher expression of AICDA than B cells from the latter subjects, and transcript levels correlated with the frequency of CXCR5(+) CD4(+) T cells. Thus, the early preservation of CXCR5(+) CD4(+) T cells and B cell function are central to the development of bNAbs. Our study provides a possible explanation for their infrequent generation during HIV-1 infection. IMPORTANCE: Broadly neutralizing antibodies are developed by HIV-1-infected subjects, but so far (and despite intensive efforts over the past 3 decades) they have not been elicited by immunization. Understanding how bNAbs are generated during natural HIV-1 infection and why only some HIV-1-infected subjects generate such antibodies will assist our efforts to elicit bNAbs by immunization. CXCR5(+) PD-1(+) CD4(+) T cells are critical for the development of high-affinity antigen-specific antibody responses. In our study, we found that the HIV-1-infected subjects who develop bNAbs have a higher frequency of peripheral CXCR5(+) PD-1(+) CD4(+) T cells in early infection and also that this frequency mirrored what was observed in uninfected subjects and correlated with the level of B cell activation across subjects. Our study highlights the critical role helper T cell function has in the elicitation of broadly neutralizing antibody responses in the context of HIV infection.

Indexed as

Antibodies, NeutralizingB-LymphocytesCohort StudiesHIV-1HIV AntibodiesHIV InfectionsHumansLongitudinal StudiesProgrammed Cell Death 1 ReceptorReceptors, CXCR5T-Lymphocytes, Helper-InducerT-Lymphocyte SubsetsAntibodies, NeutralizingCXCR5 protein, humanHIV AntibodiesPDCD1 protein, humanProgrammed Cell Death 1 ReceptorReceptors, CXCR5

Identifiers

PMID25210168
PMCPMC4249103
OpenAlexW2171487621

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.